胃癌与FGFR3相关性分析
Correlation Analysis between Gastric Cancer and FGFR3
DOI: 10.12677/jcpm.2024.32034, PDF,   
作者: 吴昱洁：青海大学研究生院，青海 西宁；李 燕*：青海大学附属医院肿瘤内科，青海 西宁
关键词: 胃癌；FGFR3；成纤维细胞生长因子受体；靶向治疗；Gastric Cancer； FGFR3； Fibroblast Growth Factor Receptor； Targeted Therapy
摘要: 胃癌是一种常见的消化系统恶性肿瘤，其发病率和病死率均居高不下。目前，针对胃癌的治疗主要包括手术切除、化疗、放疗和靶向治疗等多种方法。其中，针对肿瘤的分子特征进行个体化治疗已成为胃癌治疗的新趋势。本文综述了近年来各种FGFR3与胃癌发生及其治疗关系的研究进展，以期为胃癌的治疗提供新的分子生物靶点并促进靶向抑制剂的研究。
Abstract: Gastric cancer is a common malignant tumor of digestive system with high morbidity and mortality. At present, the treatment for gastric cancer mainly includes surgical resection, chemotherapy, radiotherapy and targeted therapy. Among them, individualized treatment based on the molecular characteristics of tumors has become a new trend in the treatment of gastric cancer. In this review, the recent research progress on the relationship between FGFR3 and the occurrence and treatment of gastric cancer is reviewed, with a view to providing new molecular biological targets for the treatment of gastric cancer and promoting the study of targeted inhibitors.
文章引用：吴昱洁, 李燕. 胃癌与FGFR3相关性分析[J]. 临床个性化医学, 2024, 3(2): 229-234. https://doi.org/10.12677/jcpm.2024.32034

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, W., Zhang, W., Wu, R., et al. (2019) Identification of Biomarkers Associated with Histological Grade and Prognosis of Gastric Cancer by Co-Expression Network Analysis. Oncology Letters, 18, 5499-5507. [Google Scholar] [CrossRef] [PubMed]
[3] 张迪, 何晶, 牛海文. 胃癌的治疗进展[J]. 新疆医学, 2021, 51(4): 464-467.
[4] Machlowska, J., Baj, J., Sitarz, M., et al. (2020) Gastric Cancer: Epidemiology, Risk Factors. Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 21, Article 4012. [Google Scholar] [CrossRef] [PubMed]
[5] Shimada, H., Noie, T., Ohashi, M., et al. (2013) Clinical Significance of Serum Tumor Markers for Gastric Cancer: A Systenatic Review of Literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 17, 26-33. [Google Scholar] [CrossRef] [PubMed]
[6] Figueiredo, C., Camargo, M.C., Leite, M., et al. (2017) Pathogenesis of Gastric Cancer: Genetics and Molecular Classification. Current Topics in Microbiology and Immunology, 400, 277-304. [Google Scholar] [CrossRef] [PubMed]
[7] Yamamoto, M., Rashid, O.M. and Wong, J. (2015) Surgical Management of Gastric Cancer: The East vs. West Perspective. Journal of Gastrointestinal Oncology, 6, 79-88.
[8] Yashiro, M. and Matsuoka, T. (2015) Sentinel Node Navigation Surgery for Gastric Cancer: Overview and Perspective. World Journal of Gastrointestinal Surgery, 7, 1-9. [Google Scholar] [CrossRef] [PubMed]
[9] Mclarnon, A. (2014) 2014 Gastrointestinal Cancers Symposium. The Lancet Oncology, 15, 262. [Google Scholar] [CrossRef] 
[10] Hudler, P. (2015) Challenges of Deciphering Gastric Cancer Heterogeneity. World Journal of Gastroenterology, 21, 10510-10527. [Google Scholar] [CrossRef] [PubMed]
[11] Marrelli, D., Polom, K., Pascale, V., et al. (2016) Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-Cardia Gastric Cancer. Annals of Surgical Oncology, 23, 943-950. [Google Scholar] [CrossRef] [PubMed]
[12] 屈晓辉, 周建华. bFGF/FGFR信号转导途径与肿瘤[J]. 国际病理科学与临床杂志, 2007, 27(2): 125-129.
[13] Katoh, M. and Katoh, M. (2006) FGF Signaling Network in the Gastrointestinal Tract (Review). International Journal of Oncology, 29, 163-168. [Google Scholar] [CrossRef] 
[14] Olsen, S.K., Garbi, M., Zampieri, N., et al. (2003) Fibroblast Growth Factor (FGF) Homologous Factors Share Structural but Not Functional Homology with FGFs. Journal of Biological Chemistry, 278, 34226-34236. [Google Scholar] [CrossRef] 
[15] Razzaque, M.S. and Lanske, B. (2007) The Emerging Role of the Fibroblast Growth Factor-23-Klotho Axis in Renal Regulation of Phosphate Homeostasis. Journal of Endocrinology, 194, 1-10. [Google Scholar] [CrossRef] 
[16] Beenken, A. and Mohammadi, M. (2009) The FGF Family: Biology, Pathophysiology and Therapy. Nature Reviews Drug Discovery, 8, 235-253. [Google Scholar] [CrossRef] [PubMed]
[17] Revest, J.M., De Moerlooze, L. and Dickson, C. (2000) Fibroblast Growth Factor 9 Secretion Is Mediated by a Non-Cleaved Amino-Terminal Signal Sequence. Journal of Biological Chemistry, 275, 8083-8090. [Google Scholar] [CrossRef] [PubMed]
[18] Goetz, R., Beenken, A., Ibrahimi, O.A., et al. (2007) Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members. Molecular and Cellular Biology, 27, 3417-3428. [Google Scholar] [CrossRef] 
[19] Hacker, U., Nybakken, K. and Perrimon, N. (2005) Heparan Sulphate Proteoglycans: The Sweet Side of Development. Nature Reviews Molecular Cell Biology, 6, 530-541. [Google Scholar] [CrossRef] [PubMed]
[20] 黄鼎智. 晚期胃癌靶向治疗进展[J]. 中国肿瘤临床, 2014, 41(1): 1408-1412.
[21] Fok, J., Ramos-Montoya, A., Vazquez-Chantada, M., et al. (2019) AZD7648 Is a Potent and Selective DNA-PK Inhibitor That Enhances Radiation, Chemotherapy and Olaparib Activity. Nature Communications, 10, Article No. 5065. [Google Scholar] [CrossRef] [PubMed]
[22] Greulich, H. and Pollock, P.M. (2011) Targeting Mutant Fibroblast Growth Factor Receptors in Cancer. Trends in Molecular Medicine, 17, 283-292. [Google Scholar] [CrossRef] [PubMed]
[23] Oki, M., Yamamoto, H., Taniguchi, H., et al. (2008) Overexpression of the Receptor Tyrosine Kinase EphA4 in Human Gastric Cancers. World Journal of Gastroenterology, 14, 5650-5656. [Google Scholar] [CrossRef] [PubMed]
[24] Wen, D., Li, S., Ji, F., et al. (2013) miR-133b Acts as a Tumor Suppressor and Negatively Regulates FGFR1 in Gastric Cancer. Tumor Biology, 34, 793-803. [Google Scholar] [CrossRef] [PubMed]
[25] Xu, C., Li, W., Qiu, P., et al. (2015) The Herapeutic Potential of a Novel Non-ATP-Competitive Fibroblast Growth Factor Receptor 1 in Hibitor on Gastric Cancer. Anti-Cancer Drugs, 26, 379-387. [Google Scholar] [CrossRef] 
[26] Schafer, M.H., Lingohr, P., Strasser, A., et al. (2015) Fibroblast Growth Factor Receptor 1 Gene Amplification in Gastric Adenocarcinoma. Human Pathology, 46, 1488-1495. [Google Scholar] [CrossRef] [PubMed]
[27] Katoh, M. (2008) Cancer Genomics and Genetics of FGFR2 (Review). International Journal of Oncology, 33, 233-237.
[28] Qiu, H., Yashiro, M., Zhang, X., et al. (2011) A FGFR2 Inhibitor, Ki23057, Enhances the Chemosensitivity of Drug-Resistant Gastric Cancer Cells. Cancer Letters, 307, 47-52. [Google Scholar] [CrossRef] [PubMed]
[29] Yashiro, M., Shinto, O., Nakamura, K., et al. (2010) Synergistic Antitumor Effects of FGFR2 Inhibitor with 5-Fluorouracil on Scirrhous Gastric Carcinoma. International Journal of Cancer, 126, 1004-1016. [Google Scholar] [CrossRef] [PubMed]
[30] Sonvilla, G., Allerstorfer, S., Heinzle, C., et al. (2010) Fibroblast Growth Factor Receptor 3-IIIc Mediates Colorectal Cancer Growth and Migration. British Journal of Cancer, 102, 1145-1156. [Google Scholar] [CrossRef] [PubMed]
[31] 钟键, 金正贤, 卞卫星, 等. 膀胱癌组织FGFR3基因突变和蛋白表达与预后关系研究[J]. 中华肿瘤防治杂志, 2020, 27(2): 130-135.